27,322 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Purchased by Capital Fund Management S.A.

Capital Fund Management S.A. bought a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 27,322 shares of the company’s stock, valued at approximately $1,130,000. Capital Fund Management S.A. owned about 0.06% of Mirum Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Jones Financial Companies Lllp lifted its stake in Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after purchasing an additional 357 shares during the last quarter. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at $69,000. AlphaQuest LLC lifted its position in shares of Mirum Pharmaceuticals by 969.6% during the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock valued at $76,000 after buying an additional 1,658 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth $189,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter worth about $215,000.

Wall Street Analyst Weigh In

MIRM has been the topic of several recent research reports. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. HC Wainwright upped their price target on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $58.20.

Insider Activity

In other news, CEO Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $327,629.04. Following the completion of the sale, the chief executive officer now directly owns 125,022 shares of the company’s stock, valued at approximately $5,991,054.24. The trade was a 5.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Peter Radovich sold 3,177 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $152,241.84. Following the completion of the transaction, the chief operating officer now directly owns 29,588 shares in the company, valued at approximately $1,417,856.96. This represents a 9.70 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 123,442 shares of company stock worth $5,568,733. 22.87% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $38.63 on Wednesday. The company’s 50 day simple moving average is $45.92 and its two-hundred day simple moving average is $44.01. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $54.23. The stock has a market capitalization of $1.89 billion, a PE ratio of -19.12 and a beta of 1.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $99.41 million during the quarter, compared to analysts’ expectations of $96.64 million. Analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.